c-Fms-IN-2

CAS No. 791587-67-2

c-Fms-IN-2( —— )

Catalog No. M26104 CAS No. 791587-67-2

c-Fms-IN-2 is an inhibitor of FMS kinase (IC50: 0.024 μM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 189 In Stock
5MG 255 In Stock
10MG 375 In Stock
25MG 562 In Stock
50MG 776 In Stock
100MG 1042 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    c-Fms-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    c-Fms-IN-2 is an inhibitor of FMS kinase (IC50: 0.024 μM).
  • Description
    c-Fms-IN-2 is an inhibitor of FMS kinase (IC50: 0.024 μM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    CSF1R
  • Recptor
    ADC Linker| Bacterial
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    791587-67-2
  • Formula Weight
    339.395
  • Molecular Formula
    C19H21N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 100 mg/mL (294.65 mM)
  • SMILES
    CC1CCN(CC1)c1ccc(CO)cc1NC(=O)c1ccc(o1)C#N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Keith Alan Charlton, et al. Methods for the Treatment of an Infectious Bacterial Disease with an Anti-Lactone or Lactone Derived Signal Molecules Antibody. US20130045208A1
molnova catalog
related products
  • JNJ-28312141 hydroch...

    JNJ-28312141 is a potent, orally active CSF-1 receptor (CSF-1R) kinase inhibitor with IC50 of 0.69 nM.

  • Edicotinib

    Edicotinib (JNJ 40346527, PRV 6527) is a potent, selective, orally bioavailable CSF-1R inhibitor with IC50 of 3.2 nM; shows weak affinity for KIT and FLT3 (IC50= 20 nM and 190 nM, respectively).

  • Pexidartinib

    An oral-active, BBB-penatrant, potent mutil-targeted RTK inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively.